InvOpps IV Form 3 Oyster Point Pharma / GP IV, L.L.C. InvOpps ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

InvOpps GP IV, L.L.C.

(Last) (First) (Middle)

126 EAST 56TH STREET, 20TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/30/2019

3. Issuer Name and Ticker or Trading Symbol
Oyster Point Pharma, Inc. [ OYST ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	(1)	(1)	Common Stock, par value $0.001 per share	609,965	(1)	I	See Footnotes(2)(4)(5)
Series B Convertible Preferred Stock	(1)	(1)	Common Stock, par value $0.001 per share	1,230,050	(1)	I	See footnotes(3)(4)(5)

1. Name and Address of Reporting Person^*

InvOpps GP IV, L.L.C.

(Last) (First) (Middle)

126 EAST 56TH STREET, 20TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

InvOpps IV US, L.P.

(Last) (First) (Middle)

126 EAST 56TH STREET, 20TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

InvOpps IV, L.P.

(Last) (First) (Middle)

126 EAST 56TH STREET, 20TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

LAINOVIC SACHA

(Last) (First) (Middle)

126 EAST 56TH STREET, 20TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Explanation of Responses:

1. These shares of Series B Convertible Preferred Stock will automatically be converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock has no expiration date.

2. Securities directly held by InvOpps IV US, L.P. ("Invus IV US").

3. Securities directly held by InvOpps IV, L.P. ("Invus IV").

4. InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.

5. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Remarks:

	INVOPPS IV US, L.P., By: InvOpps GP IV, L.L.C., its general partner, By: /s/ Sacha Lainovic, Name: Sacha Lainovic, Title: Managing Member	10/30/2019
	INVOPPS IV, L.P., By: InvOpps GP IV, L.L.C., its general partner, By: /s/ Sacha Lainovic, Name: Sacha Lainovic, Title: Managing Member	10/30/2019
	INVOPPS GP IV, L.L.C., By: /s/ Sacha Lainovic, Name: Sacha Lainovic, Title: Managing Member 10/30/2019	10/30/2019
	/s/ Sacha Lainovic	10/30/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.